EROS: Engendering Reproductive Health Within Oncologic Survivorship
PRIMARY OBJECTIVES: I. To evaluate the success of the implementation of reproductive health
programming (Didactics, Engendering Reproductive Health Within Oncologic Survivorship [EROS]
Reproductive Health Assessment and EROS Trial Algorithm) among reproductive aged women
(18-55) with cancer. SECONDARY OBJECTIVES: I. To assess the degree of discrepancy between
patients and their clinicians in estimates of significance of the reproductive health goals
for the patient. II. To evaluate baseline and follow-up reproductive health assessments for
trends in reproductive health choices relating to oncofertility, oncocontraception and
pregnancy over the 5 year study period. III. To identify clinical and demographic factors
that predict the adequacy of reproductive health care management. TERTIARY OBJECTIVES: I. To
perform a longitudinal study following endocrine markers of fertility in a cohort of the
first 200 registered EROS trial patients who agree to participate. II. To perform a
longitudinal study of sexual function using the Patient-Reported Outcomes Measurement
Information System (PROMIS) sexual function survey in all subjects participating in the EROS
Trial. OUTLINE: Patients are randomized to 1 of 2 arms. ARM A: Patients undergo usual
standard practice related to reproductive health. ARM B: Patients undergo reproductive
health program comprising didactics, reproductive health assessment and navigating
algorithm, and network development. After completion of study treatment, patients are
followed up periodically.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Adoption of appropriate reproductive health management consistent with initial reproductive health goals of the patient based on success of the EROS Trial Algorithm as a tool
The consistency rate of reproductive health management at each time point will be summarized, by arm, with frequency and percentage along with its 95% confidence interval.
Within 3 months of enrollment
No
Ashlesha Patel
Principal Investigator
Eastern Cooperative Oncology Group
United States: Institutional Review Board
E1Q11
NCT01806129
March 2013
Name | Location |
---|---|
Eastern Cooperative Oncology Group | Boston, Massachusetts 02215 |